by Raynovich Rod | Jul 6, 2012 | BIOgraph, Clinical Diagnostics and Tools
Vermillion Stock Outperforms BG Medicine Since April 3 On 4/3/12 we posted the biomarker challenge featuring two emerging public companies that have approved diagnostic products. In a few weeks we will have Q2 financial data on these two companies BG Medicine (BGMD)...
by Raynovich Rod | Feb 2, 2012 | BIOgraph, Clinical Diagnostics and Tools
Early Player in Genetic Testing and Personalized Medicine Reloads RGDX Stock Trades Up 36% on Volume of 105k Shares at $1.60 Response Genetics (RGDX) announced today that it has entered purchase agreements with private investors including current holders to raise...
by Rod Raynovich | Aug 29, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Personalized Medicine Achieves Milestone with Lung Cancer Drug Friday’s rally picked up steam today as devastation from Hurricane Irene was less than expected and consumer spending was up. Greek stocks also rallied on a bank merger. Why are Greek stocks boosting...
by Rod Raynovich | Jun 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Speculation in small cap biopharmaceutical stocks has peaked and we urged weeks ago to raise cash positions to 10-15%. The ASCO “sell on the news effect” has continued today with some high fliers off significantly: Exelixis (EXEL $8.95) is off 18% after...
by Rod Raynovich | May 24, 2011 | BIOgraph
The Life Science market consolidation trend continued today as Nestle SA acquires privately held Prometheus Laboratories, Inc. of San Diego,CA for about $567M according to a Bloomberg story although the price was not disclosed. Other stories put the price closer to...
by Rod Raynovich | May 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
But ThermoFisher (TMO $65.12) is Up 3.78% on Volume of 3.2M Shares GenProbe (GPRO $84.10) down 2.9% sold off some of of the speculative gains from yesterday after ThermoFisherScientific (TMO) announced it was buying Phadia, a privately held Swedish diagnostic Company...
by Rod Raynovich | Apr 4, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Platform Technologies Are In Demand: M&A Driver Intact Exact Sciences (EXAS $7.50) continued to run today up 3% and 1.3 pts in five days on no apparent news except presentations at recent investment conferences. The Company is developing a molecular diagnostic...
by Rod Raynovich | Mar 28, 2011 | BIOgraph
Ariad (ARIA $7.24 up 4.3%) continues to roll on today on heavy volume up 17% over 5 days on speculation, news and upgrades with strong expectations for their chronic myeloid leukemia drug ponatinib. Articles from Motley Fool, Seeking Alpha and The Street.com have...
by Rod Raynovich | Mar 23, 2011 | BIOgraph
But Cardiovascular Biomarker Indicates Anti-Inflammatory Activity For XOMA052 Xoma (XOMA $3.55) said its lead Type 2 diabetes drug-XOMA052- in a Phase 2b study failed to meet its main goal of lowering blood glucose levels. The trial failed to achieve its primary...
by Rod Raynovich | Dec 27, 2010 | BIOgraph
Vermillion (VRML) continues its wild ride upward from the November low of $4.53 on heavy volume of 546K shares with no apparent news. Two analysts cover the stock with a buy/outperform and Revenue Forecasts in the $7M range for Year Ending Dec.’11 and a Price...
